CN114286672A - 包含恩塞芬汀的药物组合物 - Google Patents

包含恩塞芬汀的药物组合物 Download PDF

Info

Publication number
CN114286672A
CN114286672A CN202080056792.8A CN202080056792A CN114286672A CN 114286672 A CN114286672 A CN 114286672A CN 202080056792 A CN202080056792 A CN 202080056792A CN 114286672 A CN114286672 A CN 114286672A
Authority
CN
China
Prior art keywords
dry powder
pharmaceutical composition
particles
powder pharmaceutical
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080056792.8A
Other languages
English (en)
Chinese (zh)
Inventor
皮特·莱昂内尔·斯帕戈
爱德华·詹姆士·弗伦奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Publication of CN114286672A publication Critical patent/CN114286672A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080056792.8A 2019-08-12 2020-08-12 包含恩塞芬汀的药物组合物 Pending CN114286672A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1911517.9A GB201911517D0 (en) 2019-08-12 2019-08-12 Pharmaceutical composition
GB1911517.9 2019-08-12
PCT/GB2020/051914 WO2021028679A1 (en) 2019-08-12 2020-08-12 Pharmaeutical composition comprising ensifentrine

Publications (1)

Publication Number Publication Date
CN114286672A true CN114286672A (zh) 2022-04-05

Family

ID=67991071

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080056792.8A Pending CN114286672A (zh) 2019-08-12 2020-08-12 包含恩塞芬汀的药物组合物

Country Status (15)

Country Link
US (1) US20220265549A1 (https=)
EP (1) EP4013384A1 (https=)
JP (1) JP7678793B2 (https=)
KR (1) KR20220045214A (https=)
CN (1) CN114286672A (https=)
AU (1) AU2020328223B2 (https=)
BR (1) BR112022002630A2 (https=)
CA (1) CA3144713A1 (https=)
GB (1) GB201911517D0 (https=)
IL (2) IL326396A (https=)
MX (1) MX2022001724A (https=)
MY (1) MY208922A (https=)
PH (1) PH12022550322A1 (https=)
WO (1) WO2021028679A1 (https=)
ZA (1) ZA202201322B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024088364A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7307855B2 (ja) * 2019-10-11 2023-07-12 テレフオンアクチーボラゲット エルエム エリクソン（パブル） 無線通信ネットワークにおける設定ダウンリンク送信および動的ダウンリンク送信をハンドリングする方法および装置
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN120787157A (zh) * 2022-10-20 2025-10-14 维罗纳制药公司 使用恩塞芬汀治疗特发性肺纤维化
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
AU2024309346C1 (en) 2023-06-26 2026-03-12 Verona Pharma Plc Particulate composition comprising ensifentrine
WO2025052119A1 (en) * 2023-09-06 2025-03-13 Verona Pharma Plc Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011746A1 (de) * 1991-12-10 1993-06-24 Boehringer Ingelheim Kg Inhalationspulver und verfahren zu ihrer herstellung
CN1942172A (zh) * 2004-03-17 2007-04-04 奇斯药制品公司 用于干粉吸入器的包含低剂量强力活性成分的药物剂型
WO2015173551A1 (en) * 2014-05-12 2015-11-19 Verona Pharma Plc New treatment
CN105142638A (zh) * 2013-03-15 2015-12-09 维罗纳制药公司 药物组合
CN107406446A (zh) * 2015-02-11 2017-11-28 维罗纳制药公司 嘧啶并[6,1‑a]异喹啉‑4‑酮化合物的盐

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60005493T2 (de) 1999-03-31 2004-07-01 Vernalis Ltd., Wokingham Pyrimido[6,1-a]isochinolinonderivate
MY196072A (en) 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011746A1 (de) * 1991-12-10 1993-06-24 Boehringer Ingelheim Kg Inhalationspulver und verfahren zu ihrer herstellung
CN1942172A (zh) * 2004-03-17 2007-04-04 奇斯药制品公司 用于干粉吸入器的包含低剂量强力活性成分的药物剂型
CN105142638A (zh) * 2013-03-15 2015-12-09 维罗纳制药公司 药物组合
WO2015173551A1 (en) * 2014-05-12 2015-11-19 Verona Pharma Plc New treatment
CN107406446A (zh) * 2015-02-11 2017-11-28 维罗纳制药公司 嘧啶并[6,1‑a]异喹啉‑4‑酮化合物的盐

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
曹伟 等: "乳糖在干粉吸入剂中的应用" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024088364A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法

Also Published As

Publication number Publication date
KR20220045214A (ko) 2022-04-12
ZA202201322B (en) 2024-06-26
IL290447A (en) 2022-04-01
BR112022002630A2 (pt) 2022-05-03
WO2021028679A1 (en) 2021-02-18
GB201911517D0 (en) 2019-09-25
WO2021028679A8 (en) 2022-02-24
CA3144713A1 (en) 2021-02-18
AU2020328223B2 (en) 2025-09-04
JP2022550664A (ja) 2022-12-05
US20220265549A1 (en) 2022-08-25
JP7678793B2 (ja) 2025-05-16
IL290447B1 (en) 2026-03-01
IL326396A (en) 2026-04-01
PH12022550322A1 (en) 2023-02-13
MY208922A (en) 2025-06-11
MX2022001724A (es) 2022-03-11
EP4013384A1 (en) 2022-06-22
AU2020328223A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
JP7678793B2 (ja) エンシフェントリンを含む医薬組成物
AU2004242450B2 (en) The treatment of respiratory diseases
JP6473738B2 (ja) チオトロピウム乾燥粉末
AU2013211656B2 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
JP2015519394A (ja) キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法
CN107205936B (zh) 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物
CN112451509B (zh) 一种川丁特罗吸入粉雾剂及其制备方法
KR20070042917A (ko) 소아 천식의 치료
US9987229B2 (en) Process for preparing a medicament
CN105338967A (zh) 包含布地奈德和福莫特罗的药物组合物
KR20100072295A (ko) 병용 요법
RU2825334C2 (ru) Фармацевтическая композиция, содержащая энсифентрин
AU2021200396B2 (en) Pharmaceutical composition containing budesonide and formoterol
KR102898819B1 (ko) 흡입용 건조 분말 제제를 위한 신규 담체 입자
EA015353B1 (ru) Применение солей тиотропия для лечения персистирующей астмы средней тяжести
CN119700722A (zh) 一种粒度分级化的布地格福吸入粉雾剂及其制备方法
MXPA06004984A (en) Soft steroid compositions for use in dry powder inhalers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination